Shea O'Connell

Dr. Shea O'Connell

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2017 in ACS Nano
Verified
Journal Article
Open access
MMMark R Miller
Mark R Miller
JRJennifer B. Raftis
Jennifer B. Raftis
JLJeremy P. Langrish
Jeremy P. Langrish
SMSteven G. McLean
Steven G. McLean
PSPawitrabhorn Samutrtai
Pawitrabhorn Samutrtai
NMNicholas Linton Mills
Nicholas Linton Mills
The development of engineered nanomaterials is growing exponentially, despite concerns over their potential similarities to environmental nanoparticles that are associated with significant cardiorespiratory morbidity and mortality. The mechanisms through which inhalation of nanoparticles could trigger acute cardiovascular events are emerging, but a fundamental unanswered question remains: Do inhaled nanoparticles translocate from the lung in man and directly contribute to the pathogenesis of cardiovascular disease? In complementary clinical and experimental studies, we used gold nanoparticles to evaluate particle translocation, permitting detection by high-resolution inductively coupled mass spectrometry and Raman microscopy. Healthy volunteers were exposed to nanoparticles by acute inhalation, followed by repeated sampling of blood and urine. Gold was detected in the blood and urine within 15 min to 24 h after exposure, and was still present 3 months after exposure. Levels were greater following inhalation of 5 nm (primary diameter) particles compared to 30 nm particles. Studies in mice demonstrated the accumulation in the blood and liver following pulmonary exposure to a broader size range of gold nanoparticles (2–200 nm primary diameter), with translocation markedly greater for particles <10 nm diameter. Gold nanoparticles preferentially accumulated in inflammation-rich vascular lesions of fat-fed apolipoproteinE-deficient mice. Furthermore, following inhalation, gold particles could be detected in surgical specimens of carotid artery disease from patients at risk of stroke. Translocation of inhaled nanoparticles into the systemic circulation and accumulation at sites of vascular inflammation provides a direct mechanism that can explain the link between environmental nanoparticles and cardiovascular disease and has major implications for risk management in the use of engineered nanomaterials.

1 February 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
SWSimon J. Wilson
Simon J. Wilson
FIFraz A. Ismat
Fraz A. Ismat
ZWZhaoqing Wang
Zhaoqing Wang
MCMichael Cerra
Michael Cerra
HNHafid Narayan
Hafid Narayan
DNDavid E. Newby
David E. Newby
Objective—: BMS-986120 is a novel first-in-class oral PAR4 (protease-activated receptor 4) antagonist with potent and selective antiplatelet effects. We sought to determine for the first time, the effect of BMS-986120 on human ex vivo thrombus formation. Approach and Results—: Forty healthy volunteers completed a phase 1 parallel-group PROBE trial (Prospective Randomized Open-Label Blinded End Point). Ex vivo platelet activation, platelet aggregation, and thrombus formation were measured at 0, 2, and 24 hours after (1) oral BMS-986120 (60 mg) or (2) oral aspirin (600 mg) followed at 18 hours with oral aspirin (600 mg) and oral clopidogrel (600 mg). BMS-986120 demonstrated highly selective and reversible inhibition of PAR4 agonist peptide (100 μM)-stimulated P-selectin expression, platelet-monocyte aggregates, and platelet aggregation ( P <0.001 for all). Compared with pretreatment, total thrombus area (μm 2 /mm) at high shear was reduced by 29.2% (95% confidence interval, 18.3%–38.7%; P <0.001) at 2 hours and by 21.4% (9.3%–32.0%; P =0.002) at 24 hours. Reductions in thrombus formation were driven by a decrease in platelet-rich thrombus deposition: 34.8% (19.3%–47.3%; P <0.001) at 2 hours and 23.3% (5.1%–38.0%; P =0.016) at 24 hours. In contrast to aspirin alone, or in combination with clopidogrel, BMS-986120 had no effect on thrombus formation at low shear ( P =nonsignificant). BMS-986120 administration was not associated with an increase in coagulation times or serious adverse events. Conclusions—: BMS-986120 is a highly selective and reversible oral PAR4 antagonist that substantially reduces platelet-rich thrombus formation under conditions of high shear stress. Our results suggest PAR4 antagonism has major potential as a therapeutic antiplatelet strategy. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT02439190.

30 March 2016 in Nanotoxicology
Verified
Journal Article
Closed access
PDF file
CSCatherine A. Shaw
Catherine A. Shaw
GMGysell M. Mortimer
Gysell M. Mortimer
ZDZhou J. Deng
Zhou J. Deng
ECEdwin S. Carter
Edwin S. Carter
SOShea O'Connell
Shea O'Connell
RMRod Minchin
Rod Minchin
In biological fluids nanoparticles bind a range of molecules, particularly proteins, on their surface. The resulting protein corona influences biological activity and fate of nanoparticle in vivo. Corona composition is often determined by the biological milieu encountered at the entry portal into the body, and, can therefore, depend on the route of exposure to the nanoparticle. For environmental nanoparticles where exposure is by inhalation, this will be lung lining fluid. This study examined plasma and bronchoalveolar fluid (BALF) protein binding to engineered and environmental nanoparticles. We hypothesized that protein corona on nanoparticles would influence nanoparticle uptake and subsequent pro-inflammatory biological response in macrophages. All nanoparticles bound plasma and BALF proteins, but the profile of bound proteins varied between nanoparticles. Focusing on diesel exhaust nanoparticles (DENP), we identified proteins bound from plasma to include fibrinogen, and those bound from BALF to include albumin and surfactant proteins A and D. The presence on DENP of a plasma-derived corona or one of purified fibrinogen failed to evoke an inflammatory response in macrophages. However, coronae formed in BALF increased DENP uptake into macrophages two fold, and increased nanoparticulate carbon black (NanoCB) uptake fivefold. Furthermore, a BALF-derived corona increased IL-8 release from macrophages in response to DENP from 1720 ± 850 pg/mL to 5560 ± 1380 pg/mL (p = 0.014). These results demonstrate that the unique protein corona formed on nanoparticles plays an important role in determining biological reactivity and fate of nanoparticle in vivo. Importantly, these findings have implications for the mechanism of detrimental properties of environmental nanoparticles since the principle route of exposure to such particles is via the lung.

1 September 2016 in Toxicology
Verified
Journal Article
Open access
DCDaniel V. Christophersen
Daniel V. Christophersen
NJNicklas R. Jacobsen
Nicklas R. Jacobsen
Maria Helena Guerra AndersenMaria Helena Guerra Andersen
Maria Helena Guerra Andersen
SOShea O'Connell
Shea O'Connell
KBKenneth K. Barfod
Kenneth K. Barfod
PMPETER MOLLER
PETER MOLLER
Exposure to high aspect ratio nanomaterials, such as multi-walled carbon nanotubes (MWCNTs) may be associated with increased risk of atherosclerosis, pulmonary disease, and cancer. In the present study, we investigated the cardiovascular and pulmonary health effects of 10 weeks of repeated oral or pulmonary exposures to MWCNTs (4 or 40μg each week) in Apolipoprotein E-deficient (ApoE-/-) mice fed a Western-type diet. Intratracheal instillation of MWCNTs was associated with oxidative damage to DNA in lung tissue and elevated levels of lipid peroxidation products in plasma, whereas the exposure only caused a modest pulmonary inflammation in terms of increased numbers of lymphocytes in bronchoalveolar lavage fluid. Ultrasound imaging in live animals revealed an increase in the inner and outer wall thickness of the aortic arch at 10 weeks after pulmonary exposure to MWCNTs, which may suggest artery remodelling. However, we did not find accelerated plaque progression in the aorta or the brachiocephalic artery by histopathology. Furthermore, repeated oral exposure to MWCNTs did not cause changes in the composition of gut microbiota of exposed mice. Collectively, this study indicates that repeated pulmonary exposure to MWCNTs was associated with oxidative stress, whereas cardiovascular effects encompassed remodelling of the aorta wall.

20 May 2019 in BJU International
Verified
Journal Article
Open access
PDF file
SOShea O'Connell
Shea O'Connell
MHMarcel Hanna
Marcel Hanna
FMFrank McCarthy
Frank McCarthy
RHRachel Hurst
Rachel Hurst
MWMartyn Webb
Martyn Webb
JCJeremy Clark
Jeremy Clark
Objectives: To develop a risk classifier using urine‐derived extracellular vesicle ( EV )‐ RNA capable of providing diagnostic information on disease status prior to biopsy, and prognostic information for men on active surveillance ( AS ). Patients and Methods: Post‐digital rectal examination urine‐derived EV ‐ RNA expression profiles ( n = 535, multiple centres) were interrogated with a curated NanoString panel. A LASSO ‐based continuation ratio model was built to generate four prostate urine risk ( PUR ) signatures for predicting the probability of normal tissue ( PUR ‐1), D'Amico low‐risk ( PUR ‐2), intermediate‐risk ( PUR ‐3), and high‐risk ( PUR ‐4) prostate cancer. This model was applied to a test cohort ( n = 177) for diagnostic evaluation, and to an AS sub‐cohort ( n = 87) for prognostic evaluation. Results: Each PUR signature was significantly associated with its corresponding clinical category ( P < 0.001). PUR ‐4 status predicted the presence of clinically significant intermediate‐ or high‐risk disease (area under the curve = 0.77, 95% confidence interval [ CI ] 0.70–0.84). Application of PUR provided a net benefit over current clinical practice. In an AS sub‐cohort ( n = 87), groups defined by PUR status and proportion of PUR ‐4 had a significant association with time to progression (interquartile range hazard ratio [ HR ] 2.86, 95% CI 1.83–4.47; P < 0.001). PUR ‐4, when used continuously, dichotomized patient groups with differential progression rates of 10% and 60% 5 years after urine collection ( HR 8.23, 95% CI 3.26–20.81; P < 0.001). Conclusion: Urine‐derived EV‐ RNA can provide diagnostic information on aggressive prostate cancer prior to biopsy, and prognostic information for men on AS . PUR represents a new and versatile biomarker that could result in substantial alterations to current treatment of patients with prostate cancer.

9 March 2020 in The Prostate
Verified
Journal Article
Open access
PDF file
SOShea O'Connell
Shea O'Connell
EOEve O'REilly
Eve O'REilly
ATAlexandra Tuzova
Alexandra Tuzova
MWMartyn Webb
Martyn Webb
RHRachel Hurst
Rachel Hurst
Daniel S BrewerDaniel S Brewer
Daniel S Brewer
Background: Prostate cancer exhibits severe clinical heterogeneity and there is a critical need for clinically implementable tools able to precisely and noninvasively identify patients that can either be safely removed from treatment pathways or those requiring further follow up. Our objectives were to develop a multivariable risk prediction model through the integration of clinical, urine‐derived cell‐free messenger RNA (cf‐RNA) and urine cell DNA methylation data capable of noninvasively detecting significant prostate cancer in biopsy naïve patients.Methods: Post‐digital rectal examination urine samples previously analyzed separately for both cellular methylation and cf‐RNA expression within the Movember GAP1 urine biomarker cohort were selected for a fully integrated analysis (n = 207). A robust feature selection framework, based on bootstrap resampling and permutation, was utilized to find the optimal combination of clinical and urinary markers in a random forest model, deemed ExoMeth. Out‐of‐bag predictions from ExoMeth were used for diagnostic evaluation in men with a clinical suspicion of prostate cancer (PSA ≥ 4 ng/mL, adverse digital rectal examination, age, or lower urinary tract symptoms).Results: As ExoMeth risk score (range, 0‐1) increased, the likelihood of high‐grade disease being detected on biopsy was significantly greater (odds ratio = 2.04 per 0.1 ExoMeth increase, 95% confidence interval [CI]: 1.78‐2.35). On an initial TRUS biopsy, ExoMeth accurately predicted the presence of Gleason score ≥3 + 4, area under the receiver‐operator characteristic curve (AUC) = 0.89 (95% CI: 0.84‐0.93) and was additionally capable of detecting any cancer on biopsy, AUC = 0.91 (95% CI: 0.87‐0.95). Application of ExoMeth provided a net benefit over current standards of care and has the potential to reduce unnecessary biopsies by 66% when a risk threshold of 0.25 is accepted.Conclusion: Integration of urinary biomarkers across multiple assay methods has greater diagnostic ability than either method in isolation, providing superior predictive ability of biopsy outcomes. ExoMeth represents a more holistic view of urinary biomarkers and has the potential to result in substantial changes to how patients suspected of harboring prostate cancer are diagnosed.